Spots Global Cancer Trial Database for ido1 inhibitor
Every month we try and update this database with for ido1 inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | NCT03335540 | Advanced Cancer | Nivolumab Relatlimab Cabiralizumab Ipilimumab IDO1 Inhibitor Radiation Thera... | 18 Years - | Bristol-Myers Squibb | |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | NCT03343613 | Solid Tumor Non Small Cell ... Renal Cell Carc... Triple Negative... | LY3381916 LY3300054 | 18 Years - | Eli Lilly and Company | |
| A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid Tumors | NCT03343613 | Solid Tumor Non Small Cell ... Renal Cell Carc... Triple Negative... | LY3381916 LY3300054 | 18 Years - | Eli Lilly and Company | |
| An Adaptive Study to Match Patients With Solid Tumors to Various Immunotherapy Combinations Based Upon a Broad Biomarker Assessment | NCT03335540 | Advanced Cancer | Nivolumab Relatlimab Cabiralizumab Ipilimumab IDO1 Inhibitor Radiation Thera... | 18 Years - | Bristol-Myers Squibb |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
